

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1612bxr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 20:02:56 ON 06 NOV 2008

=> file reg
COST IN U.S. DOLLARS
SINCE FILE ENTRY
SESSION
0.84
0.84

FILE 'REGISTRY' ENTERED AT 20:05:19 ON 06 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 NOV 2008 HIGHEST RN 1070955-84-8
DICTIONARY FILE UPDATES: 5 NOV 2008 HIGHEST RN 1070955-84-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stnqen/stndoc/properties.html>

=>
Uploading C:\Documents and Settings\brobinson1\My Documents\dafsatt.str

L1 STRUCTURE UPLOADED

```
=> s 11
SAMPLE SEARCH INITIATED 20:17:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 21 TO ITERATE
```

100.0% PROCESSED 21 ITERATIONS 13 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 146 TO 694
 PROJECTED ANSWERS: 44 TO 476

L2 13 SEA SSS SAM L1

=> s 11 full
 THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 177.90 U.S. DOLLARS
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
 FULL SEARCH INITIATED 20:17:06 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 491 TO ITERATE

100.0% PROCESSED 491 ITERATIONS 309 ANSWERS
 SEARCH TIME: 00.00.01

L3 309 SEA SSS FUL L1

=> file hcaplus
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 FULL ESTIMATED COST ENTRY SESSION
 187.10 187.94

FILE 'HCAPLUS' ENTERED AT 20:17:10 ON 06 NOV 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Nov 2008 VOL 149 ISS 19
 FILE LAST UPDATED: 5 Nov 2008 (20081105/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> s 13
 L4 9 L3

=> s 14 and bailey, m?/au
 1263 BAILEY, M?/AU
 L5 3 L4 AND BAILEY, M?/AU

=> d 15, ibib abs hitstr, 1-3

L5 ANSWER 1 OF 3 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:1009763 HCPLUS
 DOCUMENT NUMBER: 149:268327
 TITLE: Preparation of peptides as inhibitors of hepatitis C
 virus NS3 protease
 INVENTOR(S): Bailey, Murray D.; Bilodeau, Francois;
 Forgione, Pasquale; Gorys, Vida; Llinas-Brunet,
 Montse; Naud, Julie; O'Meara, Jeffrey; Poupart,
 Marc-Andre
 PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany;
 Boehringer Ingelheim Pharma G.m.b.H. & Co K.-G.
 SOURCE: PCT Int. Appl., 94pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-------------------|------------|
| WO 2008098368 | A1 | 20080821 | WO 2008-CA293 | 20080215 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRIORITY APPLN. INFO.: | | | US 2007-890304P | P 20070216 |
| OTHER SOURCE(S): | | | MARPAT 149:268327 | |
| GI | | | | |



AB The invention relates to tripeptides I [R1 is (halo)alk(en)yl; R2 is alkoxy; R2a is substituted Ph or biphenyllyl; R3 is (un)substituted alkyl, cycloalkyl, or cycloalkylalkyl; R4 is cycloalkyl, alkylcycloalkyl, or (alkyl)amino; R5 is (un)substituted alkyl or cycloalk(en)yl], including diastereoisomers, tautomers, or salts, which are useful as inhibitors of the HCV NS3 protease. Thus, tripeptide II was prepared via coupling of prolyl dipeptide and aminocyclopropanecarboxamide intermediates in the presence of HATU and diisopropylamine. Compds. of the invention show unexpectedly good activity or activity below 50 nM when tested in the NS3-NS4A protease and the cell-based luciferase reporter HCV RNA replication assays.

IT 1047995-54-9P 1047995-61-8P 1047995-66-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptides as inhibitors of hepatitis C virus NS3 protease)

RN 1047995-54-9 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-methoxy-4-[4-(3-methyl-2-furanyl)phenyl]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1047995-61-8 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-methoxy-4-[4-(1-methyl-1H-indol-5-yl)phenyl]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1047995-66-3 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-methoxy-4-[4-(3-methyl-2-thienyl)phenyl]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:15038 HCAPLUS
 DOCUMENT NUMBER: 144:108608
 TITLE: Preparation of peptide analogs as hepatitis C inhibitors
 INVENTOR(S): Bailey, Murray D.; Bhardwaj, Punit; Forgione, Pasquale; Ghiro, Elise; Goudreau, Nathalie; Halmos, Teddy; Llinas-Brunet, Montse; Poupart, Marc-Andre; Rancourt, Jean
 PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co KG; Bailey, Murray D.; Bhardwaj, Punit; Forgione, Pasquale; Ghiro, Elise; Goudreau, Nathalie; Halmos, Teddy; Llinas-Brunet, Montse; et al.
 SOURCE: PCT Int. Appl., 162 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2006000085 | A1 | 20060105 | WO 2005-CA967 | 20050622 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, | | | | |

KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM
 CA 2556669 A1 20060105 CA 2005-2556669 20050622
 EP 1763531 A1 20070321 EP 2005-759498 20050622
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
 JP 2008504240 T 20080214 JP 2007-516924 20050622
 US 20060258868 A1 20061116 US 2006-595108 20060217
 PRIORITY APPLN. INFO.: US 2004-583543P P 20040628
 WO 2005-CA967 W 20050622

OTHER SOURCE(S): CASREACT 144:108608; MARPAT 144:108608
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to peptides I [n, m are 1 or 2; R1 is H, (halo)alkyl, (halo)alkenyl or (halo)alkynyl; R2 is CH2-R7, NH-R7, O-R7, S-R7, SO-R7, SO2-R7, CH2O-R7 or O-X-R7, where X is alkylene, alkenylene or alkynylene and R7 is (un)substituted aryl or heterocyclyl; R3 is (un)substituted alkyl or cycloalkyl; R5 is B, B-CO, B-O2C, B-NR8CO, B-NR8CS, B-SO2 or B-NR8SO2, where B is (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclyl and R8 is H or alkyl; R4, R6 are independently H, (un)substituted alkyl, alkoxy, cycloalkyl, aryl or heterocyclyl; or NR4R6 may form a ring; Y is H or alkyl (with provisos)] or diastereomers or salts for the treatment and prevention of hepatitis C viral infections in mammals by inhibiting HCV NS3 protease. The invention further relates to azalactone compds. II which can be reacted with an amide anion to produce compds. I. Thus, peptide III was prepared via peptide coupling in solution with cleavage of the azalactone intermediate by sulfamoylpyrrolidine in the last step.

IT 1043019-37-9 1043019-38-0 1043019-39-1
 1043019-40-4 1043019-41-5 1043019-42-6
 1043019-43-7 1043019-44-8 1043019-45-9
 1043019-46-0 1043019-47-1 1043019-48-2
 1043019-49-3 1043019-50-6 1043019-51-7
 1043019-52-8 1043019-53-9 1043019-54-0
 1043019-55-1 1043019-56-2 1043019-57-3
 1043019-58-4 1043019-59-5 1043019-60-8
 1043019-61-9 1043019-62-0 1043019-63-1
 1043019-65-3 1043019-66-4 1043019-67-5
 1043019-68-6 1043019-69-7 1043019-70-0
 1043019-71-1 1043019-72-2 1043019-73-3
 1043019-74-4 1043019-75-5 1043019-76-6
 1043019-77-7 1043019-78-8 1043019-79-9
 1043019-80-2 1043019-81-3 1043019-82-4
 1043019-84-6 1043019-85-7 1043019-86-8
 1043019-87-9 1043019-88-0 1043019-89-1
 1043019-90-4 1043019-91-5 1043019-92-6
 1043019-93-7 1043019-94-8 1043019-95-9
 1043019-96-0 1043019-97-1 1043019-98-2
 1043019-99-3 1043020-00-3 1043020-01-4
 1043020-02-5 1043020-03-6 1043020-04-7
 1043020-05-8 1043020-06-9 1043020-07-0

1043020-11-6 1043020-15-0 1043020-18-3
 1043020-21-8 1043020-23-0 1043020-27-4
 1043020-28-5 1043020-31-0 1043020-33-2
 1043020-35-4 1043020-36-5 1043020-37-6
 1043020-38-7 1043020-39-8 1043020-40-1
 1043020-41-2 1043020-42-3 1043020-43-4
 1043020-44-5 1043020-45-6 1043020-46-7
 1043020-47-8 1043020-48-9 1043020-49-0
 1043020-50-3 1043020-52-5 1043020-53-6
 1043020-54-7 1043020-55-8 1043020-56-9
 1043020-57-0 1043020-58-1 1043020-59-2
 1043020-60-5 1043020-61-6 1043020-62-7
 1043020-63-8 1043020-64-9 1043020-65-0
 1043020-66-1 1043020-67-2 1043020-68-3
 1043020-69-4 1043020-70-7 1043020-71-8
 1043020-72-9 1043020-73-0 1043020-74-1
 1043020-75-2 1043020-76-3 1043020-77-4
 1043020-78-5 1043020-80-9 1043020-81-0
 1043020-84-3 1043020-87-6 1043020-89-8
 1043020-90-1 1043020-91-2 1043020-92-3
 1043020-93-4 1043020-94-5 1043020-95-6
 1043020-96-7 1043020-97-8


RL: PRPH (Prophetic)

(Preparation of peptide analogs as hepatitis C inhibitors)

RN 1043019-37-9 HCPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1043019-38-0 HCPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-39-1 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-40-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-41-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-42-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-43-7 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-44-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-45-9 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-46-0 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.





RN 1043019-47-1 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-48-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-49-3 HCPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-50-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-51-7 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-52-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-53-9 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-54-0 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-55-1 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-56-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-57-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-58-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-59-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-60-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-61-9 HCPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-62-0 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-63-1 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-65-3 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-66-4 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-67-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-68-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-69-7 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-70-0 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-71-1 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-72-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-73-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043019-74-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043019-75-5 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


PAGE 1-A






RN 1043019-76-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-77-7 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-78-8 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-79-9 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-80-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-81-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-82-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-84-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-85-7 HCPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-86-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-87-9 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-88-0 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-89-1 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-90-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-91-5 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-92-6 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-93-7 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043019-94-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043019-95-9 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


PAGE 1-A






RN 1043019-96-0 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-97-1 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-98-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-99-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-00-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-01-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-02-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-03-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-04-7 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-05-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-06-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-07-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-11-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-15-0 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-18-3 HCPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-21-8 HCPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-23-0 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043020-27-4 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043020-28-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


PAGE 1-A






RN 1043020-31-0 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043020-33-2 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043020-35-4 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 1043020-36-5 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 1043020-37-6 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-38-7 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-39-8 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-40-1 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-41-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-42-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-43-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-44-5 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-45-6 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-46-7 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-47-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-48-9 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-49-0 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-50-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-52-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-53-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-54-7 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-55-8 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-56-9 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-57-0 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-58-1 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-59-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043020-60-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043020-61-6 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


PAGE 1-A






RN 1043020-62-7 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-63-8 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-64-9 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-65-0 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-66-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-67-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-68-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-69-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-70-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-71-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-72-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-73-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-74-1 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-75-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-76-3 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043020-77-4 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043020-78-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


PAGE 1-A





RN 1043020-80-9 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043020-81-0 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 1043020-84-3 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-87-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-89-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-90-1 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-91-2 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-92-3 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-93-4 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-94-5 HCPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-95-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-96-7 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043020-97-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



IT 872497-04-6P 872497-05-7P 872497-09-1P
 872497-10-4P 872497-12-6P 872497-13-7P
 872497-16-0P 872497-17-1P 872497-18-2P
 872497-19-3P 872497-21-7P 872497-22-8P
 872497-33-1P 872497-34-2P 872497-35-3P
 872497-36-4P 872497-37-5P 872497-38-6P
 872497-39-7P 872497-40-0P 872497-41-1P
 872497-42-2P 872497-43-3P 872497-44-4P
 872497-45-5P 872497-46-6P 872497-47-7P
 872497-48-8P 872497-49-9P 872497-50-2P
 872497-51-3P 872497-52-4P 872497-53-5P
 872497-54-6P 872497-55-7P 872497-56-8P
 872497-57-9P 872497-58-0P 872497-59-1P
 872497-60-4P 872497-61-5P 872497-62-6P
 872497-63-7P 872497-64-8P 872497-65-9P
 872497-66-0P 872497-67-1P 872497-68-2P
 872497-69-3P 872497-70-6P 872497-71-7P
 872497-72-8P 872497-73-9P 872497-74-0P
 872497-75-1P 872497-76-2P 872497-77-3P
 872497-78-4P 872497-79-5P 872497-80-8P
 872497-81-9P 872497-82-0P 872497-83-1P
 872497-84-2P 872497-85-3P 872497-86-4P
 872497-87-5P 872497-88-6P 872497-89-7P
 872497-90-0P 872497-91-1P 872497-92-2P
 872497-93-3P 872497-94-4P 872497-95-5P
 872497-96-6P 872497-97-7P 872497-98-8P
 872497-99-9P 872498-00-5P 872498-01-6P
 872498-02-7P 872498-03-8P 872498-04-9P
 872498-05-0P 872498-06-1P 872498-07-2P
 872498-08-3P 872498-09-4P 872498-10-7P
 872498-11-8P 872498-12-9P 872498-13-0P
 872498-14-1P 872498-15-2P 872498-16-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptide analogs as hepatitis C inhibitors)

RN 872497-04-6 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-chloro-2-ethoxy-4-quinolinyl)oxy]-L-proyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-05-7 HCPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-chloro-2-ethoxy-4-quinolinyl)oxy]-L-proyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 872497-04-6

CMF C36 H49 Cl N6 O9 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 872497-09-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-10-4 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 872497-09-1

CMF C40 H54 N6 O10 S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 872497-12-6 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-7-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-13-7 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-7-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 872497-12-6
CMF C37 H51 Br N6 O10 S

Absolute stereochemistry.





CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 872497-16-0 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyloxy]-L-prolyl-1-amino-2-ethenyl-N-(4-morpholinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-17-1 HCPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-
 (4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-proyl-1-amino-2-ethenyl-N-
 (4-morpholinylsulfonyl)-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA
 INDEX NAME)

CM 1


CRN 872497-16-0
 CMF C38 H52 N6 O10 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 872497-18-2 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-proyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-19-3 HCPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 872497-18-2

CMF C36 H50 N6 O9 S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 872497-21-7 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-22-8 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 872497-21-7
CMF C35 H48 N6 O8 S2


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 872497-33-1 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(diethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-34-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(bis(1-methylethyl)amino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 872497-35-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-piperidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-36-4 HCPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-proyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-37-5 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyloxy)-L-prolyl-1-amino-N-[(3-dimethylamino)-1-pyrrolidinyl]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 872497-38-6 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyloxy)-L-prolyl-1-amino-2-ethenyl-N-[(4-methyl-1-piperazinyl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 872497-39-7 HCPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyloxy)-L-prolyl-1-amino-N-(1-azetidinylsulfonyl)-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-40-0 HCPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyloxy)-L-prolyl-1-amino-N-[(2-cyanoethyl)cyclopropylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-41-1 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2-cyanoethyl)methylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-42-2 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-proyl-1-amino-N-(aminosulfonyl)-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-43-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(4-pyridinyl)oxy)-L-proyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-44-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(4-pyridinyl)oxy)-L-proyl-1-amino-N-[(2-cyanoethyl)cyclopropylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-45-5 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(2-pyridinyloxy)-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-46-6 HCPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(4-pyridinyloxy)-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A





RN 872497-47-7 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(4-pyridinyl)oxy-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 872497-48-8 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(4-pyridinyloxy)-L-prolyl-1-amino-2-ethenyl-N-[(methylphenylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-49-9 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyloxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-50-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-51-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(ethylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-52-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-[(cyclopropylmethyl)thio]-2-ethoxy-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






RN 872497-53-5 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-[(2-methylpropyl)sulfonyl]-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-54-6 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-[(cyclopropylmethyl)sulfonyl]-2-ethoxy-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-55-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-[(phenylmethyl)sulfonyl]-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-56-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-57-9 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-58-0 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-

[(diethylamino)sulfonyl]-2-ethenyl-, (1R, 2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-59-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-60-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-

(4R)-4-[(8-bromo-2-ethoxy-7-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(diethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-61-5 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-7-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-62-6 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-chloro-2-ethoxy-4-quinolinyl)oxy]-L-proyl-1-amino-N-[(diethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-63-7 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-chloro-2-ethoxy-4-quinolinyl)oxy]-L-proyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-64-8 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-(methylthio)-4-quinolinyl)oxy]-L-proyl-1-amino-N-[(diethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-65-9 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methoxy-4-quinolinyl)oxy]-L-proyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-66-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methoxy-4-quinolinyl)oxy]-L-proyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-67-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-(methylthio)-4-quinolinyl)oxy]-L-proyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-68-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-69-3 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-70-6 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-71-7 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-72-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-73-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-74-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-75-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-2-

ethyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-76-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methoxy-4-quinolinyl)oxy]-L-proyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-77-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methoxy-4-quinolinyl)oxy]-L-proyl-1-amino-N-[(2,5-

dihydro-1*H*-pyrrol-1-yl)sulfonyl]-2-ethyl-, (1*R*,2*R*)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-78-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4*R*)-4-[(2-ethoxy-8-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethyl-N-(1-pyrrolidinylsulfonyl)-, (1*R*,2*R*)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-79-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4*R*)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-

[(dimethylamino)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-80-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-81-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-

(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-82-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-83-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-7-methoxy-4-quinolinyl)oxy]-L-proyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-84-2 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-chloro-2-ethoxy-4-quinolinyl)oxy]-L-proyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-85-3 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-86-4 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-

[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-87-5 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methoxy-4-quinolinyl)oxy]-L-proyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-88-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(ethoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-89-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methylpropoxyamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-90-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-91-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[(phenylmethyl)amino]sulfonyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-92-2 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[(4-methyl-1-piperazinyl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-93-3 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(cyclopropylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-94-4 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 872497-95-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-

[(cyanomethyl)methylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-96-6 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[(methylpropylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-97-7 HCPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[(3-hydroxy-1-pyrrolidinyl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 872497-98-8 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[(ethyl(2-hydroxyethyl)amino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-99-9 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-

[[methyl(phenylmethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-00-5 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(3-carboxy-1-piperidinyl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-01-6 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[(methylphenylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-02-7 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(4-chlorophenyl)methylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-03-8 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(4-carboxyphenyl)methylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872498-04-9 HCPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 872498-05-0 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(thieno[3,2-b]pyridin-7-yloxy)-L-prolyl-1-amino-N-

[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-06-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(5-ethoxythieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-07-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(3-phenyl-2-propynyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-08-3 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(3-cyano-6-ethoxythieno[2,3-b]pyridin-4-yl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-09-4 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(5-ethoxy-3-methylthieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-10-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(5-ethoxy-3-methylthieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-11-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(5-ethoxy-3-methylthieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-12-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[5-ethoxy-3-[(1-methylethyl)sulfonyl]thieno[3,2-b]pyridin-7-yl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-13-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-methyl-5-(1-methylethoxy)thieno[3,2-b]pyridin-7-yl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-14-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-methyl-5-(2-propenyloxy)thieno[3,2-b]pyridin-7-yl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-15-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[5-ethoxy-3-(methylsulfonyl)thieno[3,2-b]pyridin-7-yl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-16-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(5-ethoxy-2,3-dimethylthieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:1037097 HCAPLUS

DOCUMENT NUMBER: 142:38535

TITLE: Preparation of heterocyclic peptides as hepatitis C inhibitors

INVENTOR(S): Llinas-Brunet, Montse; Bailey, Murray D.;

Bhardwaj, Punit; Bordeleau, Josee; Forgione, Pasquale; Ghiro, Elise; Gorys, Vida; Goudreau, Nathalie; Goulet, Sylvie; Halmos, Teddy; Rancourt, Jean

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.


SOURCE: PCT Int. Appl., 186 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|-------------|
| WO 2004103996 | A1 | 20041202 | WO 2004-CA750 | 20040519 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004240704 | A1 | 20041202 | AU 2004-240704 | 20040519 |
| CA 2522577 | A1 | 20041202 | CA 2004-2522577 | 20040519 |
| EP 1654261 | A1 | 20060510 | EP 2004-733750 | 20040519 |
| EP 1654261 | B1 | 20071114 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| BR 2004010456 | A | 20060606 | BR 2004-10456 | 20040519 |
| CN 1791599 | A | 20060621 | CN 2004-80013783 | 20040519 |
| JP 2006528937 | T | 20061228 | JP 2006-529495 | 20040519 |
| AT 378334 | T | 20071115 | AT 2004-733750 | 20040519 |
| ES 2297424 | T3 | 20080501 | ES 2004-733750 | 20040519 |
| US 20050020503 | A1 | 20050127 | US 2004-850101 | 20040520 |
| MX 2005PA12545 | A | 20060208 | MX 2005-PA12545 | 20051121 |
| NO 2005006047 | A | 20060131 | NO 2005-6047 | 20051219 |
| IN 2005KN02624 | A | 20070727 | IN 2005-KN2624 | 20051219 |
| US 20070243166 | A1 | 20071018 | US 2007-766171 | 20070621 |
| PRIORITY APPLN. INFO.: | | | US 2003-472709P | P 20030521 |
| | | | WO 2004-CA750 | W 20040519 |
| | | | US 2004-850101 | A1 20040520 |

OTHER SOURCE(S): MARPAT 142:38535
GI



AB Peptides I [B, R3 are (un)substituted alkyl, cycloalkyl or alkylcycloalkyl; X is O or NH; R1 is Et or vinyl; RC is OH or NHSO_2RS , where RS is (cyclo)alkyl, alkylcycloalkyl, Ph, naphthyl, pyridinyl or an amino group, which are optionally substituted; R2 is R20, -NR22COR20, -NR22CO2R20, -NR22R21 or -NR22CONR21R23, where N20 is any group given for B; R21 is H or R20; R22, R23 are H or Me; L0 is H, OH, alkoxy, NH2, mono- or dialkylamino; L1, L2 are independently H, alkyl, alkoxy, alkylthio, -sulfinyl, or -sulfonyl; one of L1 and L2 may also be H; L0 and L1 or L1 and L2 may be covalently bonded to form a 5- or 6-membered ring] or their racemates, diastereoisomers, optical isomers or pharmaceutically-acceptable salts or esters were prepared as inhibitors of the hepatitis C virus (HCV) NS3 protease and are useful for the treatment of hepatitis C viral infection. Thus, I (B-X = cyclopentyloxy, R1 = vinyl, R2 = NHCOC(2)CMe_3 , RC = OH, L1 = Me, L0 = MeO, L2 = H) was prepared via peptide coupling and Mitsunobu etherification reactions. The thiazole ring was formed by reaction of a 2-(bromoacetyl)quinoline derivative with N-neopentylthiourea. Compds. I show detectable plasma levels in the rat at 1 h and 2 h after an oral dose of 5 mg/kg.

IT 801286-05-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic peptides as hepatitis C inhibitors)

RN 801286-05-5 HCAPLUS

CN Cyclopropanecarboxamide, 3-methyl-N-[[[(3S)-tetrahydro-3-furanyl]oxy]carbonyl]-L-valyl-(4R)-4-[[7-methoxy-8-methyl-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 20:02:56 ON 06 NOV 2008)

FILE 'REGISTRY' ENTERED AT 20:05:19 ON 06 NOV 2008

L1 STRUCTURE uploaded
 L2 13 S L1
 L3 309 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 20:17:10 ON 06 NOV 2008

L4 9 S L3
 L5 3 S L4 AND BAILEY, M?/AU

=> s l4 not l5
 L6 6 L4 NOT L5

=> s l6 and bhardwaj, p?/au
 55 BHARDWAJ, P?/AU
 L7 0 L6 AND BHARDWAJ, P?/AU

=> s l6 and forgione, p?/au
 89 FORGIONE, P?/AU
 L8 0 L6 AND FORGIONE, P?/AU

=> s l6 and ghiro, e?/au
 36 GHIRO, E?/AU
 L9 0 L6 AND GHIRO, E?/AU

=> s l6 and goudreau, n?/au
 44 GOUDREAU, N?/AU
 L10 0 L6 AND GOUDREAU, N?/AU

=> s 16 and halmos, t?/au
 70 HALMOS, T?/AU
 L11 0 L6 AND HALMOS, T?/AU

=> s 16 and linas-brunet, m?/au
 0 LINAS-BRUNET, M?/AU
 L12 0 L6 AND LINAS-BRUNET, M?/AU

=> s 16 and poupart, m?/au
 65 POUPART, M?/AU
 L13 0 L6 AND POUPART, M?/AU

=> s 16 and rancourt, j?/au
 133 RANCOURT, J?/AU
 L14 0 L6 AND RANCOURT, J?/AU

=> d 16, ibib abs hitstr, 1-6

L6 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:946323 HCAPLUS
 DOCUMENT NUMBER: 149:224570
 TITLE: Preparation of hydroxyproline oxime ether-containing peptide analogs as hepatitis C virus (HCV) NS3-NS4A protease inhibitors for use in pharmaceutical compositions containing a cytochrome P450 monooxygenase inhibitor
 INVENTOR(S): Sun, Ying; Or, Yat Sun; Wang, Zhe
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 175pp., Cont.-in-part of U.S. Ser. No. 758,901.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|-------------|
| US 20080187516 | A1 | 20080807 | US 2008-16631 | 20080118 |
| US 20080125444 | A1 | 20080529 | US 2007-758901 | 20070606 |
| PRIORITY APPLN. INFO.: | | | US 2006-811464P | P 20060606 |
| | | | US 2006-921488P | P 20060811 |
| | | | US 2007-758901 | A2 20070606 |

OTHER SOURCE(S): MARPAT 149:224570
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention is related to a pharmaceutical composition containing a cytochrome P 450 monooxygenase inhibitor or a pharmaceutically acceptable salt thereof and a tripeptide protease inhibitor, particularly hepatitis C virus (HCV)

NS3-NS4A protease inhibitor, I [R1, R2 = H, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, cycloalkyl, cycloalkenyl, etc.; R1R2C = atoms to form (substituted) cycloalkyl, cycloalkenyl, heterocyclyl; m, p = 0-3; n = 1-3; G = ER3; E = null, O, CO, CO2, CONH, NH, NHCONH, NHSO2NH, NHSO2; R3 = H, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl; A = R5, COR5, CONHR5, SO2R5, etc.; R5 = (substituted) aryl, heteroaryl, heterocyclyl, alkyl, cycloalkyl; B = H, Me; L, Z = H, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl] or one of its pharmaceutically-acceptable salts, esters or prodrugs. The compds. of the invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. Thus, title compound (II) (solution phase preparation given) and other I inhibited HCV NS3 proteases with IC50 values in the range of <0.2 nM to about 50 nM. Ritonavir inhibited the metabolism of I in human liver microsomes.

IT 960385-40-4P 960385-41-5P 960385-45-9P

960385-46-0P 960385-47-1P 960385-48-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(claimed compound; preparation of hydroxyproline oxime ether-containing peptide

analog as hepatitis C NS3-NS4A protease inhibitors)

RN 960385-40-4 HCPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 960385-41-5 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 960385-45-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-(1-azetidinylsulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 960385-46-0 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-(1-azetidinylsulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 960385-47-1 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 960385-48-2 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:941050 HCAPLUS
 DOCUMENT NUMBER: 149:246795
 TITLE: Preparation of 3-(quinolin-4-yl)-linked proline-containing peptidomimetics as HCV protease inhibitors
 INVENTOR(S): Yang, Syaulan; Lee, Kuang-Yuan; Chen, Rong-Juinn; Lo, Pin; Liao, Shao-Ying; Wu, Jen-Dar; King, Chi-Hsin Richard
 PATENT ASSIGNEE(S): Taigen Biotechnology Co., Ltd., Taiwan
 SOURCE: PCT Int. Appl., 71pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|--------|------------|-----------------|------------|
| WO 2008095058 | A1 | 20080807 | WO 2008-US52569 | 20080131 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| US 20080207528 | A1 | 20080828 | US 2008-23345 | 20080131 |
| PRIORITY APPLN. INFO.: | | | US 2007-887741P | P 20070201 |
| OTHER SOURCE(S): | MARPAT | 149:246795 | | |
| GI | | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to peptidomimetics I [A = cycloalk(en)ylene, alkylarylene; B = (hetero)aryl; X = O, OCH₂, CH₂O, OC(:O), COO, CONH₂, NHCO; Y, Z = independently NH and derivs., O, CH₂; D = (CH₂)_n; n = 1-2; R₁ = ORb₁, NRb₁Rb₂, NHCRb₁, NHCONHSO₂Rb₁, etc.; Rb₁, Rb₂ = independently H, heterocyclo/cyclo/alkyl, (hetero)aryl; R₂₋₁₂ = independently H, halo, alk(en/yn)yl, heterocycloalkenyl, etc.], which can be used to treat hepatitis C virus infection. Thus, II (Boc = tert-butoxycarbonyl) was prepared by a multiple-step synthesis in solution using 5,6,7,8-tetrahydroquinoline, 1-(2-amino-4-methoxyphenyl)ethanone, (4R)-N-(tert-butoxycarbonyl)-4-hydroxyproline, N-(tert-butoxycarbonyl)valine, Et (1R,2S)-1-amino-2-vinylcyclopropanecarboxylate and benzenesulfonamide. All eighty synthesized peptides exhibited inhibition of NS3/4A protease activity in the HCV replicon cell assay. (IC₅₀ values < 1 μ M for 59 compds., in the range 1-10 μ M for 14 compds. and > 10 μ M for 7 compds.).

IT 1044755-82-9P 1044755-85-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of proline-containing peptidomimetics as HCV protease inhibitors)
 RN 1044755-82-9 HCPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-L-valyl-(4R)-4-[[2-(1,3-benzodioxol-5-yl)-7-methoxy-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(cyclopropylamino)sulfonyl]-2-ethenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044755-85-2 HCPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-L-valyl-(4R)-4-[[2-(1,3-benzodioxol-5-yl)-7-methoxy-4-quinolinyl]oxy]-L-prolyl-1-amino-2-

ethenyl-N-[(1-methylethyl)amino]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:221207 HCAPLUS
 DOCUMENT NUMBER: 148:285476
 TITLE: Preparation of arylalkoxy peptides as hepatitis C serine protease inhibitors
 INVENTOR(S): Niu, Deqiang; Gai, Yonghua; Or, Yat Sun; Wang, Zhe
 PATENT ASSIGNEE(S): Enanta Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 85pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2008022006 | A2 | 20080221 | WO 2007-US75653 | 20070810 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |

PRIORITY APPLN. INFO.: US 2006-503413 A 20060811
 US 2007-836288 A 20070809
 OTHER SOURCE(S): MARPAT 148:285476
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention relates to peptides I and II [A = H, COOR1, COR2, CONHR2, SO2R1, SO2NHR2; R1 = (un)substituted (hetero)aryl, heterocycloalkyl, alk(en/yn)yl containing 0-3 heteroatoms selected from O, S or N, cycloalk(en)yl; R2, U, V = independently H, R1; G = OH, NHSO2R1; NHSO2N(R2)2; L = CH2, O, S, SO2, CO, COO, CONH, CHF, CF2, (un)substituted (hetero)arylene; X' = -X-(CH2)gC(Rx)(Ry)YZ; X = O, S, NR4; Y = absent, alk(en/yn)yl containing 0-3 heteroatoms selected from O, S or N, (hetero)cycloalkyl; Z = (un)substituted (hetero)aryl; Rx, Ry = independently any of R2; or when Rx is not H and Y is not absent, RxCRy = a ring; or when Rx is not H and Y is not absent, RxCYZ = a ring; g = 0-2; J = (CH2)^j; j = 0-4; Q = (CH2)^k; k = 1-3; D = (CH2)^m; m = 0-2; T = (CH2)ⁿ; n = 1-2] or their pharmaceutically-acceptable salts, esters or prodrugs which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease (no data). The compds. of the invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. Thus, quinolinylmethoxy macrocycle III was prepared by O-alkylation of alc. IV (preparation given) with 8-bromomethylquinoline, saponification of the Et ester and activation of the acid with CDI/treatment with cyclopropanesulfonamide. Representative compds. of the invention were found to have HCV activity in the NS3/NS4A protease enzyme assay and in the cell based replicon assay (no data).

IT 1007855-10-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of arylalkoxy peptides as hepatitis C serine protease inhibitors)

RN 1007855-10-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(2-naphthalenylmethoxy)-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 4 OF 6 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:156665 HCAPLUS

ACCESSION NUMBER: 2000.19000
DOCUMENT NUMBER: 148:239500

TITLE: Preparation of quinoxalinyl tripeptides as hepatitis C serine protease inhibitors

INVENTOR(S): Gai, Yonghua; Niu, Degiang; Or, Yat Sun; Wang, Zhe

INVENTOR(S): **Gu, Tonghua, Nia, Beiqiang, Si, Enanta Pharmaceuticals, Inc., USA**

PATENT ASSIGNEE(S): Enhanced Pharmaceuticals, Inc.
SOURCE: U.S. Pat. Appl. Publ. - 85pp

SOURCE: U.S. Pat. App.
CODEN: USXXCO

DOCUMENT TYPE: **Patent**

DOCUMENT TYPE: Patient
LANGUAGE: English

LANGUAGE: E
FAMILY ACC NUM COUNT: 1

PATENT ACC. NO. 00
PATENT INFORMATION:

| PATENT INFORMATION: | | | | |
|------------------------|------|----------|-----------------|----------|
| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
| US 20080032936 | A1 | 20080207 | US 2006-499917 | 20060804 |
| PRIORITY APPLN. INFO.: | | | US 2006-499917 | 20060804 |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention relates to tripeptides I [A = COOR1, COR2, CONHR2, SO2R1, SO2NHR2; R1, R2 = independently (un)substituted (hetero)aryl, heterocycloalkyl, alk(en/yn)yl containing 0-3 heteroatoms selected from O, S, N; cycloalk(en)yl; R, R' = independently R1, H, D, alkylcycloalk(en)yl; G = OH, NHSO2R3, NH2 and derivs.; R3 = R1; XCCY = (un)substituted (hetero)aryl; W = absent, O, S NH, Me, CONH, CONMe; Z = H, (un)substituted aryl, alkyl, heterocycloalkyl, etc.; WZ = CN, N3, halo, NHN:CHR2; B = (CH2) m ; m = 0-2; D = (CH2) n ; n = 1-2] or their pharmaceutically-acceptable salts, esters or prodrugs which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease (no data). The compds. of the invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. Thus, a

multi-step synthesis using N-(tert-butoxycarbonyl)-L-tert-leucine, cis-L-hydroxyproline Me ester, 3-(thiophen-2-yl)-1H-quinoxalin-2-one and (1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid Et ester hydrochloride was given for II. Representative compds. of the invention showed particularly advantageous biol. activity in enzyme inhibition and cell-based replicon assays for HCV activity (no data).

IT 1006051-37-1P 1006051-38-2P 1006051-86-0P
 1006051-87-1P 1006051-90-6P 1006051-91-7P
 1006051-92-8P 1006051-96-2P 1006051-97-3P
 1006052-00-1P 1006052-01-2P 1006052-02-3P
 1006052-14-7P 1006052-20-5P 1006052-21-6P
 1006052-32-9P 1006052-35-2P 1006052-37-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinoxalinyl tripeptides as hepatitis C serine protease inhibitors)


RN 1006051-37-1 HCPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyl]oxy]-L-prolyl-1-amino-2-ethenyl-N-(4-morpholinylsulfonyl)-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1006051-38-2 HCPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyl]oxy]-L-prolyl-1-amino-2-ethenyl-N-[(4-methyl-1-piperazinyl)sulfonyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006051-86-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyl]oxy]-L-prolyl-1-amino-N-(aminosulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006051-87-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006051-90-6 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(2-thiazolylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006051-91-7 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-N-[(cyclopropylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006051-92-8 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyl]oxy]-L-prolyl-1-amino-2-ethenyl-N-[(2H-tetrazol-5-ylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006051-96-2 HCPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyl]oxy]-L-prolyl-1-amino-N-(aminosulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006051-97-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006052-00-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(2-thiazolylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006052-01-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-N-[(cyclopropylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006052-02-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(2H-tetrazol-5-ylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006052-14-7 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[6,7-dimethoxy-3-(2-thienyl)-2-quinoxalinyl]oxy]-L-prolyl-1-amino-2-ethenyl-N-[(4-methyl-1-piperazinyl)sulfonyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006052-20-5 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-[2-(2-thienyl)ethyl]-2-quinoxalinyl]oxy]-L-prolyl-1-amino-2-ethenyl-N-[(2-thiazolylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1006052-21-6 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-[2-(3-methyl-2-thienyl)ethenyl]-2-quinoxalinyl]oxy]-L-prolyl-1-amino-2-ethenyl-N-[(4-methyl-1-piperazinyl)sulfonyl]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 1006052-32-9 HCPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-[2-(3-methyl-2-thienyl)ethenyl]-2-quinoxalinyl]oxy]-L-prolyl-1-amino-2-ethenyl-N-[(2-thiazolylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 1006052-35-2 HCPLUS

CN Cyclopropanecarboxamide, N-[(2-fluoroethyl)amino]carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-[2-(2-thienyl)ethyl]-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(2-thiazolylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1006052-37-4 HCPLUS

CN Cyclopropanecarboxamide, N-[(2-fluoroethyl)amino]carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-[2-(3-methyl-2-thienyl)ethenyl]-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(2-thiazolylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



L6 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:1454513 HCAPLUS
 DOCUMENT NUMBER: 148:79321
 TITLE: Preparation of hydroxyproline oxime ether-containing peptide analogs as hepatitis C virus (HCV) NS3-NS4A protease inhibitors
 INVENTOR(S): Or, Yat Sun; Sun, Ying; Wang, Zhe
 PATENT ASSIGNEE(S): Enanta Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 190pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------------------|----------|-----------------|------------|
| WO 2007146695 | A1 | 20071221 | WO 2007-US70481 | 20070606 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRIORITY APPLN. INFO.: | | | US 2006-811464P | P 20060606 |
| | | | US 2006-503385 | A 20060811 |
| OTHER SOURCE(S): | MARPAT 148:79321 | | | |
| GI | | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; R1, R2 = H, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, cycloalkyl, cycloalkenyl, etc.; R1R2C = atoms to form (substituted) cycloalkyl, cycloalkenyl, heterocyclyl; m, p = 0-3; n = 1-3; G = ER3; E = null, O, CO, CO2, CONH, NH, NHCONH, NHSO2NH, NHSO2; R3 = H, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl; A = R5, COR5, CONHR5, SO2R5, etc.; R5 = (substituted) aryl, heteroaryl, heterocyclyl, alkyl, cycloalkyl; B = H, Me; L, Z = H, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl], were prepared Thus, title compound (II) (solution phase preparation given) and other I inhibited HCV NS3 proteases with IC50 values in the range of <0.2 nM to about 50 nM.

IT 960385-40-4P 960385-41-5P 960385-45-9P

960385-46-0P 960385-47-1P 960385-48-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(claimed compound; preparation of hydroxyproline oxime ether-containing peptide

analogs as hepatitis C NS3-NS4A protease inhibitors)

RN 960385-40-4 HCPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 960385-41-5 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-

[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 960385-45-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-(1-azetidinylsulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 960385-46-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-(1-azetidinylsulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 960385-47-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 960385-48-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:451218 HCAPLUS
 DOCUMENT NUMBER: 142:482325
 TITLE: Preparation of prolyl peptides as hepatitis C virus inhibitors
 INVENTOR(S): Scola, Paul Michael; McPhee, Fiona; Meanwell, Nicholas A.; Hewawasam, Piyasena; Campbell, Jeffrey Allen
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 116 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2005046712 | A1 | 20050526 | WO 2004-US38165 | 20041112 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 20050187165 | A1 | 20050825 | US 2004-985106 | 20041110 |
| US 7132504 | B2 | 20061107 | | |
| EP 1687018 | A1 | 20060809 | EP 2004-811049 | 20041112 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU | | | | |

| | | | |
|------------------------|--|-----------------|------------|
| JP 2007534636 | T 20071129 | JP 2006-539980 | 20041112 |
| NO 2006002267 | A 20060804 | NO 2006-2267 | 20060519 |
| PRIORITY APPLN. INFO.: | | US 2003-519124P | P 20031112 |
| | | WO 2004-US38165 | W 20041112 |
| OTHER SOURCE(S): | CASREACT 142:482325; MARPAT 142:482325 | | |
| GI | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention discloses peptides I [R1, R2 are independently alkyl, cycloalkyl, alkylcycloalkyl, alkoxy, aryl, alkylaryl, cycloalkylaryl, alkoxyaryl, cycloalkoxyaryl, heteroaryl or alkylheteroaryl; or NR1R2 is monocyclic heterocyclyl; m, n are 1 or 2; R3 is H, (halo)alk(en)yl or (halo)cycloalkyl; R4 is (un)substituted alkyl, alkenyl or cycloalkyl; Y is H, nitrophenyl, nitropyridyl or (un)substituted alkyl; B is H, alkyl, acyl, (thio)carbamoyl, sulfonyl or sulfamoyl; X is O, S, SO, SO2, OCH2, CH2O or NH; R' is (un)substituted heterocyclyl or aryl (with provisos)] or their pharmaceutically-acceptable salts, solvates or prodrugs and methods for using them to inhibit the hepatitis C virus (HCV). Thus, compound II was prepared via peptide coupling in solution and showed IC50 and EC50 < 0.15 μ M for inhibition of HCV NS3/4A protease.

IT 851795-10-3P 851795-11-4P 851795-12-5P
 851795-13-6P 851795-14-7P 851795-15-8P
 851795-16-9P 851795-17-0P 851795-18-1P
 851795-19-2P 851795-20-5P 851795-21-6P
 851795-22-7P 851795-23-8P 851795-24-9P
 851795-25-0P 851795-26-1P 851795-27-2P
 851795-28-3P 851795-29-4P 851795-30-7P
 851795-31-8P 851795-33-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of prolyl peptides as hepatitis C virus inhibitors)

RN 851795-10-3 HCPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(ethylmethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-11-4 HCPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-12-5 HCPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-13-6 HCPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-(1-azetidinylsulfonyl)-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-14-7 HCPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methylphenylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-15-8 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-16-9 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methyl(1-methylethyl)amino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-17-0 HCPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-18-1 HCPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[[methyl(phenylmethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-19-2 HCPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-piperidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-20-5 HCPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(tetrahydro-2H-1,2-oxazin-2-yl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-21-6 HCPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(4-morpholinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-22-7 HCPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(4-methyl-1-piperazinyl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-23-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyloxy)-L-prolyl-1-amino-2-ethenyl-N-[(ethylmethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-24-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyloxy)-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-25-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methylphenylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-26-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-27-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-28-3 HCAPLUS


CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(ethylmethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851795-29-4 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methylphenylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851795-30-7 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methyl(1-methylethyl)amino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-31-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(1-isoquinolinylloxy)-L-prolyl-1-amino-2-ethenyl-N-[(methyl(1-methylethyl)amino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-33-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(4-pyridinyl)-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

| | | |
|--|------------------|---------------|
| => file caold | | |
| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
| FULL ESTIMATED COST | 62.50 | 250.44 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE | -7.20 | -7.20 |

FILE 'CAOLD' ENTERED AT 20:19:54 ON 06 NOV 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAOLD will be discontinued and removed from associated database clusters.

- November 22, 2008 - removed from database clusters
- December 31, 2008 - removed from STN

Content previously available only in CAOLD is now available in CA/CAplus. To learn more about the options available for transferring saved search queries and answer sets to CA/CAplus, contact your STN Service Center.

=> d his

(FILE 'HOME' ENTERED AT 20:02:56 ON 06 NOV 2008)

FILE 'REGISTRY' ENTERED AT 20:05:19 ON 06 NOV 2008

L1 STRUCTURE UPLOADED
L2 13 S L1
L3 309 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 20:17:10 ON 06 NOV 2008

L4 9 S L3
L5 3 S L4 AND BAILEY, M?/AU
L6 6 S L4 NOT L5
L7 0 S L6 AND BHARDWAJ, P?/AU
L8 0 S L6 AND FORGIONE, P?/AU
L9 0 S L6 AND GHIRO, E?/AU
L10 0 S L6 AND GOUDREAU, N?/AU
L11 0 S L6 AND HALMOS, T?/AU
L12 0 S L6 AND LINAS-BRUNET, M?/AU
L13 0 S L6 AND POUPART, M?/AU
L14 0 S L6 AND RANCOURT, J?/AU

FILE 'CAOLD' ENTERED AT 20:19:54 ON 06 NOV 2008

=> s 13
L15 0 L3

=>